Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Arbutus Biopharma Corporation ABUS
$2.56
-$0 (-0.20%)
На 18:00, 12 мая 2023
+232.03%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
425303040.00000000
-
week52high
3.15
-
week52low
1.85
-
Revenue
39019000
-
P/E TTM
-6
-
Beta
2.25397900
-
EPS
-0.46000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 11:30
Описание компании
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | Market Outperform | 28 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 14 мар 2022 г. |
| Chardan Capital | Buy | Buy | 04 мар 2022 г. |
| Jefferies | Buy | Hold | 02 февр 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 08 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Howard Elizabeth | A | 278700 | 278700 | 01 февр 2023 г. |
| Howard Elizabeth | A | 86024 | 69700 | 01 февр 2023 г. |
| Collier William H. | A | 866000 | 866000 | 01 февр 2023 г. |
| Collier William H. | A | 216500 | 216500 | 01 февр 2023 г. |
| HASTINGS DAVID C | A | 316000 | 316000 | 01 февр 2023 г. |
| HASTINGS DAVID C | A | 79000 | 79000 | 01 февр 2023 г. |
| Sofia Michael J. | A | 328700 | 328700 | 01 февр 2023 г. |
| Sofia Michael J. | A | 1385603 | 82200 | 01 февр 2023 г. |
| McElhaugh Michael J. | A | 334700 | 334700 | 01 февр 2023 г. |
| McElhaugh Michael J. | A | 1391157 | 83700 | 01 февр 2023 г. |
Новостная лента
Arbutus (ABUS) Upgraded to Buy: Here's Why
Zacks Investment Research
09 мая 2023 г. в 13:45
Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arbutus to Present at JMP Securities Life Sciences Conference
GlobeNewsWire
09 мая 2023 г. в 07:30
WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference taking place in New York on Tuesday, May 16, 2023 at 9:00 am ET.
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
04 мая 2023 г. в 11:27
Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year.
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 10:41
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.11 per share a year ago.
Arbutus Biopharma clinical hold slows hepatitis B momentum: broker
Proactive Investors
26 апр 2023 г. в 14:44
Analysts at Baird Equity Research have awarded Arbutus Biopharma a ‘Neutral' rating after the early-stage biopharmaceutical company announced that its investigational new drug application for its novel, oral PD-L1 inhibitor AB-101 for hepatitis B has been put on a clinical hold by the US Food and Drug Administration (FDA). The company said AB-101 was designed to “reawaken and boost” the immune system of chronic hepatitis B patients and believes that, when used in combination with other approved therapies, could potentially lead to a functional cure in hepatitis B patients.